Role of aflibercept for macular edema following branch retinal vein occlusion: comparison of clinical trials
Patrick Oellers,1,2 Dilraj S Grewal,1,2 Sharon Fekrat1,2 1Duke Eye Center, Duke University Medical Center, 2Surgical Service, Durham Veterans Affairs Medical Center, Durham, NC, USA Abstract: For years, the standard of care for branch-retinal-vein-occlusion-associated macular edema was initial obs...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/3c92590f7ceb47eeadd0763d90e059b6 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Patrick Oellers,1,2 Dilraj S Grewal,1,2 Sharon Fekrat1,2 1Duke Eye Center, Duke University Medical Center, 2Surgical Service, Durham Veterans Affairs Medical Center, Durham, NC, USA Abstract: For years, the standard of care for branch-retinal-vein-occlusion-associated macular edema was initial observation followed by grid-pattern laser photocoagulation for persistent edema. Newer pharmacologic options have revolutionized the management of branch-retinal-vein-occlusion-associated macular edema, and the visual outcomes of these eyes are better than ever. However, a variety of available treatment options including intravitreal corticosteroids and intravitreal anti-vascular endothelial growth factor agents have established novel challenges with regard to appropriate drug selection. This review summarizes the available clinical studies with special emphasis on the comparison of intravitreal aflibercept with ranibizumab, bevacizumab, and steroid agents. Keywords: branch retinal vein occlusion, BRVO, macular edema, cystoid macular edema, grid-pattern laser photocoagulation, triamcinolone, dexamethasone implant, ranibizumab, bevacizumab, pegaptanib, anti-vascular endothelial growth factor |
|---|